WCIRB's 10.4% Rate Filing: Pricing California's CT Claim Surge

WCIRB California's September 1, 2026 pure premium rate filing, submitted to the Insurance Commissioner on May 1, 2026, proposes advisory rates averaging 10.4% above the approved September 1, 2025 level, with the bureau citing rising cumulative trauma (CT) claim frequency, medical costs, and allocated loss adjustment expense as the primary drivers (WCIRB filing, via Insurance Journal, May 1, 2026). The bureau has not published the CT-attributable share of that 10.4%, leaving pricing actuaries to reconstruct it themselves.

That reconstruction is now possible. WCIRB's June 10, 2026 report, "Emerging Patterns of Cumulative Trauma Claims," shows CT claims reaching 26% of indemnity claims in preliminary 2024 data, up from 13% in 2012, with CT pure premium more than doubling since 2020 against roughly 30% growth for non-CT claims (WCIRB, June 10, 2026). daisyBill's June 2026 review found the bureau's public slide deck presents the CT trend contribution as unlabeled arrows in a chart titled "Components of Indicated Advisory Pure Premium Rate Change," one that does not appear in the formal filing submitted to the state (daisyBill, June 2026). The first arrow reads only "Difference to 9/1/2025 Approved," the 2.5-point gap between the 11.2% WCIRB requested for the 2025 cycle and the 8.7% the Commissioner approved. Everything past that arrow is unquantified, and the bureau's own CT report contains the raw material to fill the gap independently.

Partitioning the Loss Base Without Carrier-Level CT Flags

WCIRB does not publish a CT/non-CT split of statewide pure premium by accident year; that split lives, if anywhere, inside individual carriers' claim systems, most of which do not carry a clean CT indicator on older policy years. In the absence of that data, the bureau's published CT claim-count share, 13% of indemnity claims in 2012 rising to 26% in preliminary 2024, is the best available proxy weight for partitioning historical losses into CT and non-CT subsets. The proxy is imperfect: claim-count share is not pure-premium share, since CT claims tend to carry different average severity than non-CT claims. But WCIRB's own language narrows that gap. The bureau describes CT as "roughly a quarter" of total pure premium in the same report that puts CT claim count at 26% of indemnity claims, which means per-claim CT costs have converged toward the non-CT average even though CT indemnity severity has been flat since 2017. That convergence is itself informative: it points to CT cost growth running almost entirely through claim frequency rather than per-claim severity, a distinction the aggregate 10.4% figure erases.

With claim-count share as the weighting proxy, an actuary can build two accident-year loss triangles, CT and non-CT, by allocating each year's reported indemnity claim count, and associated losses absent a better allocator, according to the published share for that year. Interpolating between the 2012 and preliminary-2024 data points gives an approximate annual weighting series, and WCIRB's periodic CT studies provide anchor points to check that interpolation against. This is a coarser partition than a carrier could build from claim-level CT flags, and any independent estimate built this way should be documented as a reconstruction from published aggregates, not as bureau-derived truth.

Why a Blended Severity Trend Understates What Is Actually Happening

WCIRB's report states CT indemnity severity has been flat since 2017 while non-CT indemnity severity grew roughly 5% annually over the same period; CT medical severity has been flat since the pandemic against roughly 3% annual growth for non-CT medical (WCIRB, June 10, 2026). Fit a single exponential trend to blended statewide indemnity severity across both populations and the compositional shift toward the flat-severity CT segment pulls the blended trend estimate downward over time, even as non-CT severity keeps compounding at 5% a year underneath it. That is a Simpson's-paradox-style masking effect: the population mix is changing faster than the underlying per-claim cost of either subpopulation, and a trend fitted to the pooled data reflects the mix shift as much as it reflects genuine severity inflation.

The corrective test is straightforward. Fit exponential, log-linear least-squares, severity trends separately to the CT and non-CT triangles, then compare each to the blended trend fitted on pooled data over the same window. If the blended trend sits meaningfully below the non-CT-only trend, and the gap widens as the CT claim-count share climbs, that is the fingerprint of mix-shift masking rather than genuine deceleration in severity inflation. An actuary who selects a lower blended severity trend on that apparent deceleration will understate non-CT severity growth for the majority of the loss base while still missing the real CT story, because CT's cost growth is not a severity phenomenon at all.

A Worked Reconciliation of the CT-Attributable Trend Component

Consider an illustrative reconstruction using WCIRB's published ratios. Index total pure premium at 100 in 2020, split between a CT segment and a non-CT segment. Solving for the 2020 CT share consistent with WCIRB's two anchor facts, CT pure premium more than doubling (index to roughly 205 by 2024) and CT settling at roughly a quarter of total pure premium by 2024, implies a 2020 CT share of approximately 17.5%. Non-CT pure premium, growing 30% over the same four years, moves from an index of 82.5 to 107.3. CT pure premium moves from 17.5 to roughly 35.9. Total pure premium rises from 100 to approximately 143, a cumulative 43-point increase across the four years.

Decomposing that 43-point increase by source: CT contributes roughly 18.3 points and non-CT contributes roughly 24.8 points. CT claims, despite representing only about a quarter of the current pure premium base, account for approximately 42% of the four-year cumulative growth, nearly double their proportional share of the loss base. Because CT severity is essentially flat over the same window, that entire 18.3-point contribution is arithmetically a frequency effect, consistent with the claim-count evidence: a CT indemnity claim share doubling from roughly 13% to 26% lines up with CT claim frequency itself having roughly doubled since the early part of this decade. Treating the 10.4% filing as substantially trend-driven and applying that same proportional split puts the CT-attributable component in the range of 4.3 to 4.5 points, with the remaining roughly 6 points attributable to non-CT severity trend, ALAE growth, and other filing components. This is an illustrative reconstruction from published aggregate ratios, not the bureau's internal trend selection, and should be labeled as such in any work product relying on it.

Development and Tail Factor Selection for a Longer-Lag Population

CT claims warrant a separate development triangle, not just a separate trend, because their reporting and litigation pattern differs structurally from non-CT lost-time claims. WCIRB's survey of accident years 2022 through 2024 found 58% of CT claims were filed post-termination, up from 44% in a comparable survey of accident years 2013 through 2015 (WCIRB, June 10, 2026). Litigation involvement on those post-termination CT claims reached 99%, against 82% for CT claims filed while the worker was still employed (WCIRB, June 10, 2026). Both figures run far above typical litigation rates for non-CT lost-time claims. A claim filed after employment has ended, represented by counsel from the outset, develops on a different timeline than a claim reported promptly by an employed worker: first notice lags further behind the injury period, medical-legal evaluation and discovery add development stages a straightforward claim does not have, and settlement negotiations extend the tail.

The practical implication is that CT age-to-age factors should be selected from a CT-only triangle rather than borrowed from the statewide non-CT pattern, and the tail factor selection should assume a longer period before development converges to unity. Given that the post-termination share of CT claims has grown nine points across the two survey windows, and post-termination claims carry a near-universal litigation rate, the CT tail is not just longer than non-CT, it is getting longer, which argues against holding a static CT tail factor across successive rate reviews.

ALAE: Medical-Legal and Interpreter Costs Do Not Belong in the Medical Trend

Medical-legal services (AME and QME evaluations) accounted for 37% of paid medical costs on CT claims in the most recent data, up from 24% in the 2017-2019 period (WCIRB, June 10, 2026). Interpreter service cost per CT claim has grown to more than six times 2014 levels by 2024 (WCIRB, June 10, 2026). Neither cost driver behaves like ordinary medical treatment cost. Medical-legal evaluation fees follow a separate fee schedule and scale with the number of panel evaluations a litigated claim generates, not with utilization of treatment services; interpreter cost scales with the number of hearings, depositions, and medical-legal appointments a claim requires, which is itself a function of litigation intensity. Folding both into a blended medical severity trend overstates the medical-treatment component of that trend while understating how much of CT cost growth is actually a litigation-driven ALAE phenomenon.

The cleaner treatment separates the two. Medical severity trend should be fit to treatment cost net of medical-legal evaluation charges, ideally referencing the state's official medical fee schedule utilization trend. Medical-legal and interpreter costs should be trended separately and loaded into the ALAE provision, where their growth rate, which is running well ahead of general medical trend on the evidence above, can be tracked and reviewed on its own cycle rather than smoothed into a single medical severity number that obscures both components.

Classification-Level Implications for Schedule Rating

Statewide, the CT surge is not evenly distributed across classifications. Public safety and correctional classifications carry elevated physical and psychological trauma exposure and, in several cases, statutory injury presumptions that lower the evidentiary bar for a CT claim; healthcare classifications carry high patient-handling and musculoskeletal exposure; warehousing and distribution classifications carry high-frequency repetitive-motion exposure from scanning, lifting, and material handling. Actuaries building class-level indications or reviewing schedule and individual risk rating plans should compare each classification's CT claim share against the statewide 26% benchmark rather than assume the statewide average applies uniformly.

Because the CT surge documented in the June 2026 report is concentrated in accident years since roughly 2020, classification relativities built from experience periods that predate the surge will understate current CT-driven cost in the classes most exposed to it. That creates a specific credibility problem for individual risk and schedule rating: up-weighting recent policy periods captures the CT trend faster, but the longer CT reporting and litigation tail means recent-period losses are also the least mature, so an actuary who simply shifts experience-period weighting toward recent years without adjusting for CT's longer development lag risks understating the ultimate cost of exactly the risks the reweighting was meant to capture more accurately.

Documenting an Independent Estimate Under ASOP 41

When a bureau's own public exhibits do not reconcile, presenting an independently derived CT trend component to underwriting or a regulator carries a documentation obligation. ASOP No. 41, Actuarial Communications, requires disclosure of the data and assumptions an estimate relies on, including reliance on data or information supplied by others. A defensible communication built on the methodology above should state plainly that the CT/non-CT split is a reconstruction from WCIRB's published aggregate claim-count share and cost ratios, not from carrier-level CT-flagged data; that the reconciliation of the CT-attributable trend component to the 10.4% filing is a proportional allocation built on published ratios rather than the bureau's internal selection; and that the estimate should be presented as a range given the coarseness of the claim-count proxy. That disclosure is what separates an independent estimate from restating the bureau's unquantified figure with more confidence than the data supports.

Why This Matters for Pricing Actuaries

WCIRB's June 2026 CT report gives pricing actuaries the component data the bureau's own rate filing exhibits do not assemble into a usable trend. A split-trend model built from claim-count share weighting, separate CT and non-CT severity and development triangles, and a distinct ALAE treatment for medical-legal and interpreter cost produces a defensible, documentable estimate of how much of the 10.4% average increase traces to cumulative trauma claims specifically, rather than accepting or disputing the aggregate figure without being able to show the work. For classifications with disproportionate CT exposure, that decomposition also changes the classification relativity and schedule rating conversation ahead of the September 1, 2026 effective date, because a statewide average increase applied uniformly across classes will overcharge classes with below-average CT exposure and undercharge the public safety, correctional, healthcare, and warehousing classes carrying the bulk of the surge.